Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 and High-Dose Cytarabine in Myeloid Blast Crisis CML
NCT00015834Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2001
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myeloid leukemia (CML), sponsored by National Cancer Institute. Primary endpoints: Toxicity according to NCI/NIH Common Toxicity Criteria up to 2 years, Hematologic response up to 6 months and 1 more. Started May 2001; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00015834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015834.